Melatonin in the treatment of low back pain and predictors of its efficacy
Курганова Ю. М., Данилов А. Б.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 117, Вып. 10, С. 49-54
Опубликовано: 2017
Тип ресурса: Статья
DOI:10.17116/jnevro201711710149-54
Аннотация:
Objective. To assess analgesic properties of melatonin in the treatment of chronic non-specific low back pain and to study predictors of its efficacy. Material and methods. A study included 178 patients, aged from 40 to 65 years, with chronic nonspecific low back pain during >3 month and the VAS score >3. Patients were stratified into 6 groups (3 pairs of comparison). In the first pair, patients of both groups received a combination of 500 mg of glucosamine hydrochloride and 500 mg of chondroitin sulfate; in the second pair — a combination of 500 mg of glucosamine hydrochloride and 500 mg of chondroitin sulfate and diclofenac, in the third pair — diclofenac. All patients received additionally melaxen. The duration of the study was 3 month in the first pair and one month in the second and third pairs. With regard to response to melatonin, patients of the main groups were divided into responders and non-responders. Baseline factors determining the efficacy of treatment with melatonin wer
Ключевые слова:
Chronic pain; Low back pain; Melatonin; Treatment
chondroitin sulfate; diclofenac; glucosamine; melatonin; analgesic agent; chondroitin sulfate; diclofenac; glucosamine; melatonin; adult; analgesic activity; Article; comorbidity assessment; controlled study; depression; drug efficacy; human; low back pain; major clinical study; middle aged; pain intensity; rest; sleep disorder; treatment response; aged; chronic pain; combination drug therapy; comparative study; complication; female; low back pain; male; movement (physiology); pain measurement; treatment outcome; Adult; Aged; Analgesics; Chondroitin Sulfates; Chronic Pain; Diclofenac; Drug Therapy, Combination; Female; Glucosamine; Humans; Low Back Pain; Male; Melatonin; Middle Aged; Movement; Pain Measurement; Sleep Wake Disorders; Treatment Outcome
Язык текста: Русский
ISSN: 2309-4729
Курганова Ю. М. Юлия Михайловна 0001-
Данилов А. Б. Андрей Борисович 1962-
Kurganova Yu. M. Yuliya Mikhaylovna 0001-
Danilov A. B. Andrej Borisovich 1962-
Melatonin in the treatment of low back pain and predictors of its efficacy
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 117, Вып. 10 С. 49-54
2017
Статья
Chronic pain Low back pain Melatonin Treatment
chondroitin sulfate diclofenac glucosamine melatonin analgesic agent chondroitin sulfate diclofenac glucosamine melatonin adult analgesic activity Article comorbidity assessment controlled study depression drug efficacy human low back pain major clinical study middle aged pain intensity rest sleep disorder treatment response aged chronic pain combination drug therapy comparative study complication female low back pain male movement (physiology) pain measurement treatment outcome Adult Aged Analgesics Chondroitin Sulfates Chronic Pain Diclofenac Drug Therapy, Combination Female Glucosamine Humans Low Back Pain Male Melatonin Middle Aged Movement Pain Measurement Sleep Wake Disorders Treatment Outcome
Objective. To assess analgesic properties of melatonin in the treatment of chronic non-specific low back pain and to study predictors of its efficacy. Material and methods. A study included 178 patients, aged from 40 to 65 years, with chronic nonspecific low back pain during >3 month and the VAS score >3. Patients were stratified into 6 groups (3 pairs of comparison). In the first pair, patients of both groups received a combination of 500 mg of glucosamine hydrochloride and 500 mg of chondroitin sulfate; in the second pair — a combination of 500 mg of glucosamine hydrochloride and 500 mg of chondroitin sulfate and diclofenac, in the third pair — diclofenac. All patients received additionally melaxen. The duration of the study was 3 month in the first pair and one month in the second and third pairs. With regard to response to melatonin, patients of the main groups were divided into responders and non-responders. Baseline factors determining the efficacy of treatment with melatonin wer